TAIO PHAR |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8,580 JPY | -0.12% |
|
-.--% | -0.75% |
ETFs positioned on TAIO PHAR
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.83% | 4 M€ | +3.24% | ||
| 0.79% | 15 M€ | +11.75% | ||
| 0.19% | 1,120 M€ | +1.88% | ||
| 0.05% | 18 M€ | +16.15% | - | |
| 0.04% | 20,721 M€ | +15.40% | - | |
| 0.04% | 144,586 M€ | +16.55% | ||
| 0.04% | 66,066 M€ | +16.86% | - | |
| 0.02% | 773 M€ | -.--% | - | |
| 0.02% | 7 M€ | +3.48% | - | |
| 0.01% | 60 M€ | +16.25% | ||
| 0.01% | 10 M€ | -3.35% | - | |
| 0.00% | 31 M€ | +5.22% | - | |
| 0.00% | 389 M€ | +7.11% | - | |
| 0.00% | 34 M€ | +6.21% | - | |
| 0.00% | 39 M€ | +3.82% | - | |
| 0.00% | 302 M€ | +4.66% | - | |
| 0.00% | 34 M€ | +2.67% | - |
Taisho Pharmaceutical Holdings Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture and sale of over-the-counter drugs, quasi-drugs, foods, medical supplies, hygiene products, and ethical drugs. The Company operates in two business segments. The Self-Medication segment is engaged in the research, development, manufacture and sale of over-the-counter drugs, quasi-drugs, foods, medical supplies, hygiene products. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of ethical drugs. The other business is engaged in the leasing and management of real estate, as well as hotel management business.
Sector
-
Calendar
2024-05-12
- Q4 2023 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TAIPY Stock
- 4581 Stock
- Funds and ETFs TAIO PHAR
